Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Glucagon-like peptide-1 receptor (GLP-1) agonists, widely used to treat obesity and diabetes, may also improve key outcomes for patients with Crohns disease, according to a large real-world study presented during the 2026 Crohns & Colitis Congress, a partnership of AGA and the Crohn's & Colitis Foundation, taking place in Las Vegas
Together, these inputs help preserve lean mass during periods of weight change
While the findings are intriguing and introduce a novel player in the field, substantial questions remain before this pathway can be considered a strong candidate for obesity drug development, Marzieh Salehi, an endocrinologist at the University of Texas Health at San Antonio, told DDN
In the state of brain insulin resistance, insulin signaling pathways such as the PI3K/Akt pathway become abnormal, and abnormalities in insulin signaling pathways lead to a decrease in A clearance, which promotes A deposition (Zheng and Wang, 2021)
When an incident occurs, act quickly and methodically to reduce harm and meet compliance obligations
US$ 27.68
US$ 28.64
US$ 25.32
US$ 28.55
US$ 20.19
